biology (field) – Talk Bio

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

1 month ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer

Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology

2 months ago talkbio0Tagged biology (field), Capital, Fund I, Geographic Intersection, Investments, Michael Langer, Robert Langer, Technology, venture capital

T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

6 months ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

9 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology

10 months ago talkbio0Tagged Alanine Transaminase, Artificial Intelligence, biology (field), Bioptimus, Cathay Innovation, Drug Industry, medical innovation, Study models

Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.

Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases

11 months ago talkbio0Tagged Age-Related Diseases, BioAge Labs, biology (field), Exercise, Homo sapiens, Longevity, Longevity Data, Novartis, research, targets

Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration

Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership

1 year ago talkbio0Tagged Artificial (qualifier value), Artificial Intelligence, biology (field), Biotechnology, Broad Institute, gene therapy, IMMUNODEFICIENCY, COMMON VARIABLE, 10, R. Liu, research

AI drug discovery, Basecamp Research, Broad Institute, David R. Liu, Biotechnology, Gene therapy, Artificial intelligence in biology

Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD

1 year ago talkbio0Tagged Approved, biology (field), Chronic Obstructive Airway Disease, Dupixent, Regeneron, sanofi, United States Food and Drug Administration

Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron

AstraZeneca Secures FDA Approval for Fasenra in Rare Autoimmune Disorder EGPA

1 year ago talkbio0Tagged Approved, Asthma, AstraZeneca, Autoimmune Diseases, biology (field), Eosinophilic granulomatosis with polyangiitis, Infrequent, United States Food and Drug Administration

AstraZeneca, Fasenra, FDA approval, EGPA, rare autoimmune disorder, asthma biologic

AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease

1 year ago talkbio0Tagged Approved, asthma medication, AstraZeneca, Autoimmune Diseases, biology (field), eosinophilic, Eosinophilic granulomatosis with polyangiitis, Granulomatosis, GSK 's, Infrequent, Nucala, Systemic Vasculitis, United States Food and Drug Administration

AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala